A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Must have received: systemic therapy

Subjects must exhibit relapsed or refractory disease following prior systemic therapy, which may include autologous hematopoietic stem cell transplantation.

Cannot have received: allogeneic hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation prior to the administration of the investigational drug

Cannot have received: autologous hematopoietic stem cell transplantation

Exception: within six months preceding study drug administration

Autologous hematopoietic stem cell transplantation within six months preceding study drug administration

Cannot have received: golidocitinib (golidocitinib)

Previous use of golidocitinib

Cannot have received: pomalidomide (pomalidomide)

Previous use of pomalidomide

Cannot have received: cytotoxic chemotherapy

Exception: must not have been terminated within 21 days before the start of the study

Cytotoxic chemotherapy must not have been terminated within 21 days before the start of the study

Cannot have received: systemic antineoplastic therapy

Exception: within four weeks of study initiation

Received systemic antineoplastic therapy (including macromolecular monoclonal antibodies and immunotherapy drugs) within four weeks of study initiation

Cannot have received: radiation therapy

Exception: within three weeks

received radiation therapy within three weeks

Cannot have received: toxin/isotope-immune antibody conjugates

Exception: within ten weeks

Received other toxin/isotope-immune antibody conjugates within ten weeks

Cannot have received: experimental drug or investigational drug

Exception: within 30 days prior to study commencement

Received an experimental drug or investigational drug in another trial within 30 days prior to study commencement